Evidera

Evidera provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products. The company offers a comprehensive suite of services including Real-World Evidence & Data Solutions, Non-Interventional Studies, Interventional Studies, Patient-Centered Research, Evidence Synthesis, Modeling & Communication, Strategic Development Consulting, Value & Access Consulting, Medical Writing, and Implementation Science. With over 35 years of leadership and experience, Evidera was originally created in 2013 and acquired by PPD in 2016. The company has legacy brands such as MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes. Evidera employs over 750 staff from more than 45 nationalities and operates 8 primary offices across North America and Europe. The company has published over 2,400 peer-reviewed articles and has 1,300+ studies in progress across all major therapeutic areas. Evidera has supported 150+ drugs and therapies in the past year, including 9 of the top 10 selling drugs in the past 5 years, and has partnered with every one of the top 20 biopharmaceutical companies and over 250 small and mid-sized biotechnology companies. The company has expanded its real-world and patient-centered research capabilities in China, Japan, and beyond through collaborations with HLT and CSS. Evidera provides tailored evidence generation strategies from regulatory to clinical to real-world and offers medical writing services for the peri- and post-approval phases of the product lifecycle. The company has executed over 290 interventional studies in the past five years involving approximately 113,000+ patients, conducted studies across 70+ countries and in 115+ disease areas, and developed the first consortium-developed PRO instrument, the EXACT-PRO, with qualification statements from both the FDA and EMA. Additionally, Evidera developed the Alzheimer’s Disease ACE, a comprehensive multi-application disease simulator, and offers a cloud-based platform called LiveTracker® for dynamic, real-time syndicated data to monitor and anticipate market changes for commercialized products. The company provides strategic guidance to help determine the best approaches for generating the right evidence to improve a product’s value proposition and market access potential, and has a global network of over 2.2 million healthcare providers. Evidera also publishes The Evidence Forum, addressing scientific and strategic challenges in healthcare.